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Abstract
Background: Early prostate cancer antigen (EPCA) has been shown a prostate cancer (PCa)-associated nuclear matrix
protein, however, its serum status and prognostic power in PCa are unknown. The goals of this study are to measure serum
EPCA levels in a cohort of patients with PCa prior to the treatment, and to evaluate the clinical value of serum EPCA.
Methods: Pretreatment serum EPCA levels were determined with an ELISA in 77 patients with clinically localized PCa who
underwent radical prostatectomy and 51 patients with locally advanced or metastatic disease who received primary
androgen deprivation therapy, and were correlated with clinicopathological variables and disease progression. Serum EPCA
levels were also examined in 40 healthy controls.
Results: Pretreatment mean serum EPCA levels were significantly higher in PCa patients than in controls (16.8467.60 ng/ml
vs. 4.1262.05 ng/ml, P,0.001). Patients with locally advanced and metastatic PCa had significantly higher serum EPCA level
than those with clinically localized PCa (22.9365.28 ng/ml and 29.4168.47 ng/ml vs. 15.1766.03 ng/ml, P=0.014 and
P,0.001, respectively). Significantly elevated EPCA level was also found in metastatic PCa compared with locally advanced
disease (P,0.001). Increased serum EPCA levels were significantly and positively correlated with Gleason score and clinical
stage, but not with PSA levels and age. On multivariate analysis, pretreatment serum EPCA level held the most significantly
predictive value for the biochemical recurrence and androgen-independent progression among pretreatment variables
(HR=4.860, P,0.001 and HR=5.418, P,0.001, respectively).
Conclusions: Serum EPCA level is markedly elevated in PCa. Pretreatment serum EPCA level correlates significantly with the
poor prognosis, showing prediction potential for PCa progression.
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Introduction
Prostate cancer (PCa) has emerged as the most commonly
diagnosed malignancy and the second leading cause of cancer-
related death among men in the great majority of Western
countries [1]. Its incidence is rapidly increasing in China [2,3].
Although the majority of patients diagnosed with PCa are
currently found to have clinically localized disease [4], and local
therapies with curative intent such as radical prostatectomy (RP)
and radiotherapy can provide effective and durable disease
control, approximately one third of those patients eventually
experience biochemical recurrence [5,6], which is often due to the
early dissemination of microscopic metastatic disease that remains
undetected by currently conventional pretreatment staging
modalities such as radionuclide bone scan, computerized tomog-
raphy (CT) scan, and magnetic resonance imaging. For locally
advanced and metastatic PCa, androgen deprivation therapy
(ADT) remains the most important and the primary treatment [7],
which can lead to symptomatic improvement and a reduction in
serum prostate specific antigen (PSA) levels in most patients.
However, almost all these patients ultimately progress to hormone
independence, which remains the main obstacle to improving
survival and quality of life in these patients [8,9]. In this context, it
is of important interest to identify markers that are able to
recognize patients prone to undergo disease progression, thereby
helping to optimize therapy decisions for the individual patient.
The widespread use of PSA test has led to increased detection of
the disease at earlier stages and a reduction in the number of
patients where metastatic disease is found at diagnosis. However,
serum PSA is not independently diagnostic or prognostic in
human PCa due to its significant limitations in the specificity and
sensitivity [10–12]. Therefore, there is an urgent need for novel
and improved serum prognostic biomarkers to be identified in
PCa.
The nuclear matrix is responsible for maintaining nuclear
shape, function, and organization of its components. The changes
of its protein components have been associated with malignant
transformations and translated to potential clinical applications
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nuclear matrix proteins that are associated with PCa development
and correlated with poor prognostic features [16,17]. Early
prostate cancer antigen (EPCA) is a prostate cancer (PCa)-
associated nuclear structural protein, which was discovered by
Dhir et al in 2004 and identified as being expressed throughout the
prostate of patients with PCa but not in those without the disease
[18]. In the same study, the positive immunostaining for EPCA
protein was also noted in the benign prostatic glands of the
negative biopsies from men who were eventually diagnosed with
prostate carcinoma as much as 5 years later [18]. Using an indirect
enzyme linked immunosorbent assay (ELISA), Paul et al [19]
firstly analyzed the plasma samples from a series of 46 individuals,
including 12 PCa patients, 16 healthy donors, and 18 patients with
other cancers or benign conditions. They found that mean plasma
EPCA level in the patients with PCa was significantly higher than
each of the other populations, and that the plasma EPCA, at a
cutoff of 1.7 absorbance at 450 nm, had a sensitivity of 92% (11/
12) for PCa patients, a specificity of 100% (16/16) for healthy
donors, and an overall specificity of 94% (32/34) for entire donor
controls. In two recent studies, we measured the EPCA levels in
serum from men with isolated high-grade prostatic intraepithelial
neoplasia (HGPIN) [20] and men with symptomatic benign
prostatic hyperplasia (BPH) who underwent transurethral resec-
tion of the prostate (TURP) [21]. We found that elevated serum
levels of EPCA were significantly correlated with increased risk of
the subsequent PCa onset in HGPIN during a period of $5 years
follow-up and the incidental PCa presence on TURP specimens
analysis. All these findings suggest that up-regulation of EPCA
may be involved in the presumably earlier stage of prostatic
carcinogenesis and that circulating EPCA can be used as a
potential diagnostic and predictive marker in human PCa.
Recently, Leman et al [22] reported that the serum level of
EPCA-2.22, one epitope of the EPCA-2 protein (another nuclear
matrix protein different from EPCA) in patients with nonorgan-
confined PCa was higher than that in those with organ-confined
disease, thus ELISA assay for serum EPCA-2.22 level can
accurately differentiate between organ-confined and nonorgan-
confined disease. However, to the best of our knowledge, there are
no published reports on serum status of EPCA and its association
with clinical outcomes in PCa patient. In this study, we investigate
the EPCA expression status in serum using an ELISA method in a
large consecutive cohort of patients with PCa comprising clinically
localized carcinomas who underwent radical prostatectomy (RP)
and locally advanced and metastatic disease who received
androgen-deprivation therapy (ADT) as a single treatment. We
further analyzed the association of pretreatment serum EPCA
level with established clinicopathological parameters of PCa, as
well as the relationship between the pretreatment serum EPCA
level and the onset of biochemical progression and hormone-
resistant phenotype. Measurement of EPCA in blood samples
could be useful for the clinical management of PCa.
Results
Clinical and pathological characteristics
Pretreatment data regarding initial serum PSA levels, Gleason
scores, and T classification were available for all 128 studied
patients. Their clinical and pathological characteristics are detailed
in Table 1. In all, 77 (60.2%) patients with localised small volume
cancers confined to the prostate were staged as T1-T2/N0/M0,
20 (15.6%) patients with bulky locally advanced disease staged as
T3-T4/N0/M0, and 31 (24.2%) patients with evidence of
metastatic spread staged as N+/M+. The mean patients age,
weight, height, body mass indices, and initial PSA level were
63.365.7 years (median: 65 years, range: 46–78 years), 74.26
5.1 kg (median: 76 kg, range: 58–84 kg), 170.265.0 cm (median:
172 cm, range: 155–183 cm), 23.4462.82 kg/m
2 (median:
21.67 kg/m
2, range: 17.62–28.21 kg/m
2), and 12.6466.17 ng/
ml (median: 10.56 ng/ml, range: 2.20–130.84 ng/ml), respective-
ly. The mean age of healthy control group was 64.166.0 years
(median: 66 years, range: 45–80 years).
Follow-up results
No patient was lost to follow-up. All patients had regular PSA
measurements from the time of surgery or the initiation of ADT
through the follow-up period. The mean and median length of
follow-up was 39.4 and 35.8 months (range: 2–72 months),
respectively. For 77 prostatectomy patients, 19 (24.7%) cases
developed the biochemical progression during the follow-up. The
mean and median time from RP to biochemical recurrence were
27.4 and 24.5 months (range: 2–49.9 months), respectively.
Among the 51 patients with locally advanced and metastatic
PCa who were treated by ADT as the primary treatment, 39
(76.5%) cases were identified as having AIP after the initiation of
ADT. The mean and median time from the ADT initiation to AIP
in this cohort were 25.8 and 21.3 months (range: 6–52 months),
respectively.
Baseline serum levels of EPCA in healthy controls and
PCa patients
EPCA was detectable in the sera from all healthy control
subjects and PCa patients. The measurement results of serum
EPCA in normal healthy controls and PCa patients are shown in
Table 2. Obviously, the mean serum EPCA levels were
significantly different between the healthy subjects and cancer
patients (P,0.001). When the results from the three groups of
patients with clinically localized PCa (T1-T2), locally advanced
PCa (T3-T4), and metastatic disease were individually compared
Table 1. Clinical and Pathologic Features of 128 Patients with
PCa.
Characteristics N (%)
Initial serum PSA levels
0–2.5 5 (3.9)
2.6–4.0 16 (12.5)
4.1–9.9 40 (31.3)
$10.0 67 (52.3)
Gleason score
2–4 16 (12.5)
5–6 68 (53.1)
7 24 (18.8)
8–10 20 (15.6)
Clinical TNM stage
T1N0M0 20 (15.6)
T2N0M0 57 (44.5)
T3N0M0 7 (5.5)
T4N0M0 13 (10.2)
T(any)N+M0 10 (7.8)
T(any)N(any)M+ 21 (16.4)
doi:10.1371/journal.pone.0019284.t001
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any of the three groups (all Ps,0.001). Moreover, patients with
metastatic PCa had significantly higher serum EPCA levels than
those in the both groups of patients with clinically localized PCa
and locally advanced disease (P,0.001 and P,0.001, respective-
ly). Significantly elevated levels of EPCA were also found in
patients with locally advanced PCa as compared with the clinically
localized PCa (P=0.004). In addition, serum EPCA levels between
PCa patients with lymph node metastases and distant organ
metastases (bone and liver) was not significantly different
(P=0.28). Likewise, two groups of ADT treated patients who
received LHRH agonists plus antiandrogen agents and who
received bilateral orchidectomy plus antiandrogen agents had
similar serum EPCA levels (P=0.31).
Association of pretreatment serum EPCA levels with
clinicopathologic characteristics of PCa Patients
Table 2 also shows the correlation between EPCA levels and
clinicopathologic features in patients with PCa. Pretreatment
serum EPCA levels were significantly elevated in PCa patients
with higher Gleason score (P,0.001), clinical advanced stage
(P,0.001), and metastatic status (P,0.001). From the Kruskal–
Wallis test, the pretreatment serum EPCA level was significantly
and positively correlated with tumour Gleason score. The Mann-
Whitney test also showed a significant and positive correlation
between the serum EPCA expression level and clinical stage.
Tumours with Gleason score 7–10 or stage T3-T4 tended to have
a significantly higher serum EPCA expression level than those with
Gleason score #6 or T1-T2 stage. Furthermore, we also found
that pretreatment serum EPCA level was significantly associated
with metastatic disease. PCa patients with metastases tended to
have a significantly higher EPCA expression level in their sera
than those with localized carcinomas. To evaluate the association
between pretreatment serum EPCA levels and the disease
progression, we assessed the changes of serum EPCA levels at
the time points of presentation prior to treatment between patients
with disease progression and those without. Analysis of the
measurements revealed that all patients with progressive disease
had significantly higher levels of serum EPCA (mean:
28.5565.76 ng/ml, range: 19.20–45.82 ng/ml) than those with-
out progression (mean 13.8264.50 ng/ml, range: 5.20–22.45 ng/
ml, P,0.001). However, the mean serum EPCA level in patients
with biochemical progression after RP (27.8566.14 ng/ml, range:
19.20–43.60 ng/ml) was not significantly different from that in
those with AIP after the initiation of ADT (30.3667.52 ng/ml,
range: 21.00–45.82 ng/ml, P=0.280).
The initial serum PSA levels in this cohort were compared with
their pretreatment serum EPCA levels. However, no statistically
significant correlation between serum EPCA and PSA levels was
identified (P=0.274). Although the elder men (.65 years)
appeared to have an increased serum EPCA level, the serum
EPCA level did not statistically correlate with patient age
(P=0.102). The univariate analysis further demonstrated that
pretreatment serum EPCA level was not correlated with initial
serum PSA levels (correlation coefficient=0.148, P=0.173) and
patients age (correlation coefficient=0.082, P=0.316).
Association of pretreatment serum EPCA levels with
biochemical progression after RP
To further assess the relationship between pretreatment serum
EPCA levels and the onset of biochemical recurrence after RP, we
performed a Kaplan-Meier progression-free actuarial probability
curve in the 77 patients with clinically localized PCa who were
treated with RP. As shown in Figure 1, the Kaplan-Meier analysis
revealed that patients with elevated pretreatment serum EPCA
levels (greater than the median value of 15.20 ng/ml) had an
increased probability of PSA progression (log-rank test, P,0.001).
At a mean follow-up of 39.4 months, the biochemical progression-
free survival probability of patients with clinically localized PCa
was 52.8% in 36 cases with pretreatment serum EPCA level
.15.20 ng/ml in the serum in comparison with the rate of 95.1%
in the remaining 41 cases with pretreatment serum EPCA level
#15.20 ng/ml (P,0.001). Moreover, the mean time from RP to
biochemical recurrence in patients with pretreatment serum
EPCA levels .15.20 ng/ml (20.4 months, range: 2–35.8 months)
was significantly shorter than that in those with pretreatment
serum EPCA levels #15.20 ng/ml (36.7 months, range: 23.5–49.9
months, P,0.001). On the univariate analysis, serum EPCA level
was significantly associated with the risk of PSA progression
following RP (Table 3, P,0.001), along with Gleason score
(Table 3, P=0.016). On a preoperative multivariate model, the
association between serum EPCA level and biochemical progres-
sion remained statistically significant (Table 3, P,0.001), and the
HR was 4.860 (Table 3, 95%CI: 2.070–6.035) for pretreatment
Table 2. Baseline serum levels of EPCA in healthy controls
and PCa patients and association of EPCA levels with
clinicopathological variables in 128 prostatic carcinomas.
Characteristics
Mean±SD
(ng/ml)
Median
(ng/ml)
Range
(ng/ml)
Group
Healthy controls (n=40) 4.1262.05 3.35 0.68- 8.77
PCa patients (n=128) 16.8467.60 15.20 5.20–45.82
p Value1 ,0.001*
Age (year)I
#65 17.8267.50 14.95 5.20–35.30
.65 19.0368.28 16.19 10.35–45.82
p Value1 0.102*
Clinical stage
T1-T2 15.1766.03 13.85 5.20–20.25
T3-T4 22.9365.28 19.80 13.60–40.00
p Value1 ,0.001*
Gleason score
2–6 13.3664.02 12.00 5.20–21.00
7 21.6168.11 18.53 12.90–35.30
8–10 31.0869.24 28.25 20.25–45.82
p Value1 ,0.001{
Initial serum PSA level (ng/ml)
#10 19.5068.42 17.72 10.35–45.82
.10 18.7467.60 16.90 5.20–35.30
p Value1 0.274*
Metastatic status{
Yes 29.4168.47 28.00 21.00–45.82
No 14.8366.25 12.90 5.20–23.43
p Value1 ,0.001*
ICategorized by the median value.
*Mann-Whitney U test.
{Kruskal-Wallis test.
{Including lymph node metastases and distant metastases to bone and liver.
1p,0.05, statistically significant.
doi:10.1371/journal.pone.0019284.t002
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Gleason sum had not independent prognostic value of the
biochemical progression (Table 3). These data demonstrate that
pretreatment serum EPCA is a significant predictor for the
development of biochemical progression postoperatively in
patients with clinically localized PCa.
Association of pretreatment serum EPCA levels with
androgen-independent progression
To further assess the relationship between pretreatment serum
EPCA levels and the appearance of AIP, we performed a Kaplan-
Meier AIP-free actuarial probability curve in the 51 patients with
locally advanced or metastatic PCa who were treated with ADT as
the sole treatment. The Kaplan-Meier analysis revealed that
patients with pretreatment serum EPCA level .15.20 ng/ml had
a significantly increased probability of the development of AIP
(Figure 2, log-rank test, P,0.001). Following a mean follow-up of
39.4 months (range: 2–72 months) after the initiation of ADT, the
AIP-free survival probability was 9.3% for 33 men with
pretreatment serum EPCA level .15.20 ng/ml compared to the
rate of 61.1% for the rest 18 men with serum EPCA level
#15.20 ng/ml (P,0.001). The mean time for achieving a status of
AIP was 12.4 months (range: 6–21.5 months) in patients with
serum EPCA level .15.20 ng/ml and 35.2 months (range: 20.6–
52 months) in patients with serum EPCA level #15.20 ng/ml,
respectively. The Kaplan–Meier curve demonstrated that patients
Figure 1. Kaplan-Meier estimates of PSA progression-free survival probability for the 77 patients with clinically localized PCa
treated with RP, who were grouped by the baseline serum EPCA level above or below the median value of 15.20 ng/ml.
doi:10.1371/journal.pone.0019284.g001
Table 3. Univariate and multivariate Cox regression analyses of pre-operative variables for the prediction of biochemical
progression after RP for 77 patients with clinically localized PCa.
Univariate Multivariate
Variables Hazard Ratio 95%CI p Value1 Hazard Ratio 95%CI p Value1
Preoperative EPCA levels 5.232 3.172–7.145 ,0.001 4.860 2.070–6.035 ,0.001
Initial PSA levels* 2.633 1.214–4.115 0.083 1.825 0.738–2.924 0.140
Clinical stage{ 1.527 0.653–2.431 0.172 0.818 0.374–1.623 0.202
Gleason score{ 3.044 1.242–4.329 0.016 2.102 1.053–3.720 0.114
*Initial PSA levels were categorized as $10 ng/ml versus ,10 ng/ml.
{Clinical stage was categorized as T1 versus T2.
{Gleason score was categorized as grade 2 to 6 versus grade 7 to 10.
1p,0.05, statistically significant.
doi:10.1371/journal.pone.0019284.t003
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time for the presence of AIP than those with serum EPCA level
.15.20 ng/ml (P,0.001). Furthermore, an univariate Cox
proportional hazard model analysis showed that those patients
with elevated serum EPCA level prior to the ADT had a
significantly increased risk of the onset of AIP compared with those
with pretreatment serum EPCA#15.20 ng/ml (Table 4,
P,0.001). Also, the initial PSA level and the clinical stage were
significantly correlated with the risk of AIP (Table 4). On a
multivariate model, the pretreatment serum EPCA level remained
a statistically significant association with the presence of AIP after
androgen suppression, with a HR of 5.418 (Table 4, 95%CI:
3.637–7.251, P,0.001), whereas the other variables like the
clinical stage and the initial PSA level did not (Table 4). These
data demonstrate that pretreatment serum EPCA is a significant
predictive variable for the development of AIP in patients with
locally advanced and metastatic disease.
Discussion
To date, no validated serum biomarker has been identified with
prognostic power in human PCa. In this study, using an ELISA
test, we demonstrated a significantly elevated serum EPCA level in
patients with PCa in comparison with the normal healthy men
without cancer. We found that patients with metastatic PCa had a
significantly higher EPCA level in serum than those with clinically
Figure 2. Kaplan-Meier estimates of AIP-free survival probability for the 51 patients with locally advanced and metastatic PCa
treated with ADT, who were grouped by the baseline serum EPCA level above or below the median value of 15.20 ng/ml.
doi:10.1371/journal.pone.0019284.g002
Table 4. Univariate and multivariate Cox regression analyses of pre-treatment variables for the prediction of AIP after ADT for 51
patients with locally advanced or metastastic PCa.
Univariate Multivariate
Variables Hazard Ratio 95%CI p Value1 Hazard Ratio 95%CI p Value1
Preoperative EPCA levels 6.825 3.702–8.436 ,0.001 5.418 3.637–7.251 ,0.001
Initial PSA levels* 2.702 1.106–4.035 0.025 1.213 0.482–2.428 0.140
Clinical stage{ 3.533 2.146–5.126 0.002 1.626 0.759–3.035 0.108
Gleason score{ 2.237 1.002–3.724 0.114 1.051 0.442–2.132 0.262
*Initial PSA levels were categorized as $10 ng/ml versus ,10 ng/ml.
{Clinical stage was categorized as T3-T4 versus N+/M+.
{Gleason score was categorized as grade 2 to 6 versus grade 7 to 10.
1p,0.05, statistically significant.
doi:10.1371/journal.pone.0019284.t004
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prospective cohort of PCa patients, the serum EPCA level of
locally advanced PCa patients was significantly higher than that of
clinically localized PCa patients. These data suggest an association
of serum EPCA with the malignant phenotype of prostatic
carcinoma.
Thus, we studied the association between serum EPCA levels
and clinicopathological features of PCa patients. In the present
128 patients, pretreatment serum EPCA levels were significantly
and positively correlated with the clinical risk factors of poor
prognosis such as Gleason score and stage. We found that patients
with high Gleason score ($7) or advanced clinical stage (T3-T4 or
N+/M+) tended to have higher serum EPCA levels prior to the
treatment. These findings are not in accordance with previous
immunohistochemical studies, where the significant and positive
correlation between EPCA expression levels in PCa tissue and
tumor stage was not found [18,28]. This discrepancy may be
related to the different sensitivity of the assays and the difference of
the protein levels expressed in blood and tissue. In a previous study
on circulating EPCA levels in PCa patients performed by Paul and
coworkers [19], the plasma EPCA levels was not significantly
correlated with Gleason grade because the Gleason Score was
either 6 or 7 in all but one patient, whereas the association
between the plasma EPCA level and tumor stage was not
examined. In the same study, they also reported that no
statistically significant correlation was identified between the
plasma EPCA level and PSA level because most of the PSA levels
fell within the clinically indistinguishable range of 4–10 ng/ml.
Concordantly with this result, we found in the present study that
the serum EPCA levels were not correlated with initial serum PSA
levels. Our findings suggest that serum levels of EPCA expression
are positively associated with tumor burden independently of
serum PSA. The studies described here were not designed to
examine the serum EPCA levels after RP or ADT but from the
recent reports that serum level of EPCA-2.22 after RP was
significantly lower than that before surgery (P,0.001) and
considered to be normal postoperatively [22], it would seem that
the levels of serum EPCA fall following the ablation of the
prostatic cancer. The previous reports have shown that patients
age probably does not influence EPCA levels in the plasma in a
relatively small-sized population [19]. To address whether the
observed elevation of serum EPCA level in patients with PCa was
age dependent, we compared their median age (and range) with
that of the healthy controls. We found that the median age (and
range) was not significantly different from each other. Moreover,
PCa patients of age .the median value of 65 years had the similar
EPCA level in serum to those of age #65 years (P=0.102). Taken
together, we can exclude the possibility of age-dependent
expression of serum EPCA in patients with PCa. Additionally,
the serum EPCA levels were not significantly different between
patients with lymph node metastases and distant organ metastases,
indicating that baseline serum EPCA levels were independent of
the metastatic sites.
Furthermore, we investigate the correlation of pretreatment
serum concentrations of EPCA with PCa progression to
biochemical relapse or androgen-independence. The results
suggested that disease progression may occur earlier in those
PCa patients with an elevated pretreatment serum EPCA level,
and that the elevated EPCA level in serum may be an early event
during the disease progression of human PCa. Initial serum PSA
level, tumor Gleason score, and clinical stage are pretreatment
factors related to clinical risk of human PCa. Some authors
reported that these variable did not predict the interval to disease
progression [26,29]. Concordantly with these authors, we found
that initial PSA level, Gleason grade, and clinical stage were not
associated with cancer progression in the present study. Although
the univariate analysis showed that the tumor Gleason score had
significance in predicting the biochemical progression after RP in
patients with clinically localized PCa, and that the initial PSA level
and tumor clinical stage were significantly predictive of the time to
AIP in patients with locally advanced or metastatic PCa under
androgen suppression as a single therapy, all these variables lost
their statistical significance on the multivariate analyses. In this
cohort of patients, the multivariate Cox proportional hazards
models demonstrated that the elevated pretreatment serum EPCA
held the most significantly predictive value for the disease
progression among these pretreatment factors.
The highly variable nature of PCa progression constitutes a
major problem in clinical management of the individual patient.
The identification of more validated markers that advance the
ability to predict the clinical progression and prognostic outcome
of the disease would help to optimize therapy decisions. In
addition, with the continued widespread use of PSA-based
screening, current patients who undergo RP have lower levels of
PSA, which further supports the need for novel serum markers
that better predict disease outcome in these patients. Our results
showed that the elevated serum EPCA level can be detected
significantly sooner than the presence of biochemical recurrence
after radical surgery in clinically localized PCa and the oneset of
AIP after ADT in locally advanced or metastatic PCa. Based upon
those data, there are at least two potential clinical benefits to the
identification of pretreatment serum EPCA levels. The first is
prognostic: higher pretreatment serum EPCA level may add useful
prognostic information above and beyond traditional clinical risk
factors for the disease progression. Therefore, measurement of
serum EPCA levels with ELISA before RP has the potential to
identify patients at high risk of postoperatively biochemical
recurrence, thereby provides timely information to guide postop-
erative neoadjuvant or adjuvant intervention. Also, higher serum
EPCA level in PCa patients beginning ADT may provide
important and unique information. For example, a study of
chemotherapy in castration-sensitive prostate cancer might limit
eligibility to patients with elevated serum EPCA levels present to
enrich for a particularly poor prognostic cohort. The second is
therapeutic: based upon the results presented here, we suggest that
the analysis of EPCA in serum might help to identify patients who
benefit from early multimodal therapy and might facilitate a new
therapeutic strategy that may compensate for current limitations of
diagnosis based on serum PSA alone. In patients with presumed
organ-confined PCa, the measurement of serum EPCA before RP
may alter the surgical approach. Nerve sparing RP has been
recently used to preserve erectile function. With this approach the
distance between the prostatic capsule and surgical margin is
significantly decreased. Studies have addressed the potential cure
rate when wider surgical excision of the neurovascular bundle is
performed in patients with extraprostatic tumor [30,31]. There-
fore, preoperative measurement of serum EPCA by ELISA may
help identify cases in which nerve sparing RP should not be
considered due to the presence of extraprostatic tumor extension.
Our study was limited by the small-sized sample. The follow-up
time was relatively short (median: 35.8 months) in the present
study, nonetheless, our results have significant clinical implications
for human PCa because the risk of cancer specific mortality is
especially greater in patients with PSA recurrence within the first 3
years after RP [32]. In addition, there were relatively many
patients with advanced PCa in this study (extraprostatic in 40% of
the patients). Because there is no PSA-based screening programme
for PCa in China, more patients are diagnosed with locally
Serum EPCA Level and PCa Progression
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screening [2,3]. Thus, there could be differences if our data are
transferred to other populations, especially in a screened
population. Despite the limitations of this hospital based cohort
study, our results demonstrate the potential of serum EPCA as a
prognostic predictor in PCa progression by phenotype manifesta-
tion in survival analysis. If the findings presented here are
corroborated by larger population cohort studies and in more
races, EPCA may become an important biomarker and an
indicator for distinct therapy options.
In summary, this prospective study investigates the pretreatment
EPCA level in serum and its association with clinical outcome in a
cohort of patients with PCa. The pretreatment serum EPCA levels
are markedly elevated in PCa patients, and significantly correlated
with high Gleason grade and clinical advanced stage indepen-
dently of the serum PSA levels and patients age. Furthermore, our
results add to the literature by documenting the significance of
baseline serum EPCA level as a distinct predictor of disease
progression comprising biochemical recurrence and AIP in human
PCa. Although extensive clinical trials are required to confirm
these findings, this initial study shows that measurement of
pretreatment serum EPCA may be of clinical importance and may
help to identify cancer patients at increased risk of tumor
progression, thereby optimizing therapeutic decisions for the
individual patient.
Materials and Methods
Patient population and treatment
From July 2004 to July 2010, we prospectively evaluated 128
consecutive patients with prostatic adenocarcinoma who were
diagnosed and treated at Minimally Invasive Surgery Center
(MISC), Guangzhou Medical College. All the patients were staged
by digital rectal examinations (DRE) and transrectal ultrasound
(TRUS) for local disease and by bone scanning and CT of the
abdomen and pelvis for metastatic disease according to the 2002
American Joint Committee on Cancer (AJCC) TNM classification
criteria [23]. All patients had histopathological confirmation of the
diagnosis of PCa based on examination of prostatic tissues
obtained by TRUS-guided prostate biopsy or by TURP. The
histologic grade of the tumor was determined using the Gleason’s
score system [24]. Of these 128 patients, 77 men (60.2%) had
clinically localized PCa and were treated by retropubic radical
prostatectomy (RP). The remaining 51 patients (39.8%) were
diagnosed as having locally advanced (n=20) and metastatic PCa
(n=31). The metastatic disease included lymph node metastases in
10 patients, distant metastases to bone in 19 and to liver in 2
patients. All the 51 patients received androgen-deprivation
therapy (ADT) as the sole treatment. The type of ADT was
chemical [i.e. luteinizing hormone–releasing hormone (LHRH)
agonists plus antiandrogen agents] in 27 patients and surgical (i.e.
bilateral orchidectomy plus antiandrogen agents) in the remaining
24 patients. All patients had no evidence of active infection or
inflammatory disease. No patients were treated before collecting
blood samples.
This study also included 40 normal healthy men without cancer,
who were presenting for prostatic cancer screening at our MISC.
They had no prior history of cancer and chronic disease, normal
DRE findings, and a PSA level ,2.0 ng/ml, which is in the PSA
range with an estimated PCa detection probability of less than 1%
in the first 4 years after screening [25]. Prior to commencing this
study, the approval from the Ethics Review Board of Guangzhou
Medical College was granted and the written informed consent
was obtained from each patient.
Serum samples and EPCA measurement
Blood samples were prospectively collected from 128 PCa
patients by drawing on the morning of the scheduled day of RP or
on the morning of the starting day of ADT after a pretreatment
overnight fast. For patients who underwent TRUS-guided needle
biopsy of the prostate, the blood samples were drawn at least 4
weeks after the biopsy. The blood samples from 40 normal healthy
men were also drawn on the morning of the scheduled day of
visiting after a overnight fast. The samples were collected into
evacuated tubes, and serum was separated within 1 h of blood
collection after centrifuging at 3,000 rpm for 10 min at room
temperature. The serum was subsequently decanted using sterile
transfer pipettes and stored immediately at 280uC until analysis.
We have established the optimal conditions for the indirect
ELISA for the measurement of serum EPCA protein in a pilot
study [21]. The specificity and sensitivity for serum EPCA in
discriminating PCa were 98.0% and 100%, respectively [21]. In
the present study, a commercially available anti-EPCA polyclonal
antibody (Onconome Inc., Seattle, Washington, USA) was used,
and the procedure of ELISA for EPCA measurement was
performed as described previously [21]. Briefly, serum samples
from each patient were plated in triplicate in 96-well Nunc
Immunoplate MaxiSorb plates (Nunc, Wiesbaden, Germany).
When the reaction was stopped, the plates were read at 450 nm on
the LabSystems Multiskan Multisoft microplate reader (LabSys-
tems, Helsinki, Finland). The concentration that corresponds to
the absorbance level in each sample was calculated from the
standard curve equation. The mean of the three measurements for
each sample were used for data analyses. The differences among
the measurements were minimal, with the intra-assay precision
coefficients of variation of ,10%. In this study, all assays were
performed by an experienced laboratory expert at our institute
(L.O.), who was blinded with respect to the case status of the
samples. Elevated serum level of the EPCA was defined as being
greater than the median value of 15.20 ng/ml in this studied
cohort of patients.
Follow-up and definitions of progression
All patients were continuously seen by the urologists in our
Department from the date of RP or ADT. Each of the 77 patients
who underwent RP was scheduled to undergo a DRE and assay of
serum PSA level starting 4 weeks postoperatively, every 3 months
for the first postoperative year, semiannually from the second
through the fifth year, and annually thereafter. In the 51 patients
with locally advanced or metastatic PCa who received ADT,
serum PSA was determined every three months until androgen-
independent progression (AIP) occurred. The primary outcome
variables were biochemical progression after RP for patients with
clinically localized PCa and time to AIP during treatment with
ADT for those with locally advanced or metastatic disease.
Biochemical progression was defined as a sustained elevation of
serum PSA level .0.2 ng/ml on two or more occasions, and the
date of progression was assigned as the date of the first PSA
increase value .0.2 ng/ml. The AIP was defined as two
consecutive rises of serum PSA (at least 1 week apart) greater
than the nadir value while receiving ADT. The nadir PSA was
defined as the minimal serum PSA observed during the follow-up
[26]. The time to the AIP during ADT was defined as the duration
of time from the initiation of ADT to the date of AIP or was
censored among patients who did not progress at the date last
known progression free or the date of death who died without
progression [7,27]. In this study, disease progression was defined
as either the appearance of biochemical progression in clinically
localized PCa or the onset of AIP in locally advanced or metastatic
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the nearest month, taken from the time of presentation to the time
of death/last follow-up. Pretreatment and posttreatment serum
PSA concentrations for each patient were measured always by
using a Hybritech AccessH PSA assay (Beckman Coulter, Inc.,
Fullerton, CA).
Statistical analysis
Patient clinical characteristics were summarized as number and
percentage of patients or median and range of values. The
association between the serum EPCA levels and different
clinicopathological features was assessed by use of the Mann-
Whitney test and the Kruskal-Wallis test, as appropriate. The
Kaplan-Meier method was used to calculate survival functions,
and differences were assessed by log-rank analysis. Univariate and
multivariate survival analyses were performed with the Cox
proportional hazards regression model. The hazard ratio (HR)
with 95% confidence interval (CI) was calculated to determine the
power of parameters for predicting the disease progression.
Pretreatment parameters were assessed in terms of pretreatment
serum EPCA level, initial PSA level, Gleason score, and clinical
stage. Pretreatment EPCA level was used as a continuous variable,
which was dichotomized at the median value within the cohort.
Clinical stage was entered as a categorical variable and evaluated
as T1–2 versus T3–4. Gleason score were entered as categorical
variables and evaluated as grade 2 to 6 versus grade 7 to 10. All
reported P values represent two-sided tests of statistical signifi-
cance. In this study, a P,0.05 was considered as statistically
significant. All statistical analyses were performed with the
Statistical Package for the Social Sciences (SPSS) statistical
software package version 13.0 for Windows (SPSS, Inc, Chicago,
IL, USA).
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